-Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
Belén Garijo to become Chief Executive Officer of Sanofi Sanofi's Board of Directors met on February 11, 2026, and decided not to renew the Direc...
Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Ad...
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. announced ...
Elecoglipron demonstrated a favorable safety and tolerability profile in Chinese adults living with obesity/overweight with or without type 2 diabete...
Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-...
Azenta, Inc. announced a strategic partnership with Frontier Space, a pioneer in commercial space-based research systems, to conduct cutting-edge s...
EpimAb Biotherapeutics, a clinical stage biopharmaceutical company specializing in the development of novel multispecific antibodies,announced the achiev...
– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority co...
New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including C...
Novel approach attacks production of polyamines that tumors require to proliferate and suppress the immune system Aminex Therapeutics, Inc., a...
Initiative will create one of the world's largest multimodal cancer datasets and an integrated suite of AI models and tools to fuel p...
BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm, announced the successful acquisition of Bi...
Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.6...
© 2026 Biopharma Boardroom. All Rights Reserved.
